Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. (ACRS): 14 pipeline candidates · 1 upcoming catalyst · ~17 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
17.0 months
D/E 0.38 · 0% dilution
Lead: Approved
14 candidates
1 upcoming, next in ~3303d
0 buys · 1 sell (180d)
A transparent, data-derived signal for Aclaris Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$617.3M
Cash
$28.7M
Quarterly Burn
$18.1M
Runway
17.0 mo
Revenue
$2.0M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (14 candidates)
| Drug | Phase |
|---|---|
| ATI-045 | Phase 2 |
| ATI-052 | Phase 2 |
| ATI-1777 | Phase 2 |
| ATI-2138 | Phase 2 |
| ATI-450 | Phase 2 |
| ATI-9494 | Preclinical |
| Bosakitug (ATI-045) | Phase 2 |
| Denosumab | Phase 1 |
| eskata | Approved |
| Lepzacitinib (ATI-1777) | Phase 2 |
Showing 10 of 14 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
133
Total value held
$322.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 10,334,938 | $38.8M |
| deep track capital, lp | 9,345,000 | $35.0M |
| blackrock, inc. | 7,407,065 | $27.8M |
| ra capital management, l.p. | 6,804,072 | $25.5M |
| rock springs capital management lp | 4,472,650 | $16.8M |
| adage capital partners gp, l.l.c. | 3,871,000 | $14.5M |
| balyasny asset management l.p. | 3,361,328 | $12.6M |
| kalehua capital management llc | 3,169,921 | $11.9M |
| woodline partners lp | 2,971,246 | $11.1M |
| citadel advisors llc | 2,818,019 | $10.6M |
Showing top 10 of 133 institutional holders of Aclaris Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Aclaris Therapeutics, Inc.'s pipeline?
Aclaris Therapeutics, Inc. (ACRS) has 14 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aclaris Therapeutics, Inc.'s lead drug candidate?
Aclaris Therapeutics, Inc.'s most advanced tracked candidate is ATI-045 (Phase 2) for Atopic Dermatitis.
What is Aclaris Therapeutics, Inc.'s next catalyst?
Aclaris Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ESKATA" — expected July 4, 2035.
What is Aclaris Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aclaris Therapeutics, Inc. has approximately 17.0 months of cash runway.
What is Aclaris Therapeutics, Inc.'s market capitalization?
Aclaris Therapeutics, Inc.'s market capitalization is approximately $617.3M.
Get the full picture on Aclaris Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.